Abstract:To evaluate the treatment effects of combined therapy using Doxorubicin and radiofrequency hyperthermia and expound the mechanism of local Chemotherapy under the heat-stress condition in vitro and in a rabbit VX2 liver tumor model Institutional Animal Care and Use Committee approved all studies. In vitro experiments VX2 cell lines cultured and were randomly assigned to four treatment groups, namely. Group A, phosphate-buffered saline (n = 6); group B, 5 μΜ Doxorubicin alone; hroup C, 42°C culture for 20 min (n = 6); and group D, 5 μΜ doxorubicin plus under 42°C culture for 20 min (n = 6). The viability and doxorubicin uptake of VX2 tumor cells line were assayed by flow cytometer and fluorescence microscopy at 24h after different treatment. Western blot was used to evaluate the Hsp70 expression. Tumor tissues were harvested from our Prestudy of rabbit liver VX2 tumor model. Fluorescence microscopy observed the distribution of doxorubicin, Hsp70 activity was analyzed by Western blot and Immunohistochemistry. P <0.05 was considered statistically significant. Radiofrequency hyperthermia-induced apoptosis and necrosis in VX2 cells in a mechanism of enhancing doxorubicin dose in cell and Hsp 70 expression. Fluorescence microscopy showed a further increase doxorubicin concentration in tumor cells and the penetration depth in tumor tissue. The western blot result showed Hsp70 expression in the combined group was significantly greater than in the control groups (mean ± SEM: 0.15 ± 0.03 vs. 0.64 ± 0.13 vs. 0.83 ± 0.10 vs. 1.28 ± 0.13, P <0.05). In the tumor tissue, immunohistochemistry staining results showed the significant increase of Hsp70-positive signaling was observed in RFH combined doxorubicin group than control group (P <0.01). Significantly increased of the tumor apoptosis and necrosis also found in the combined group with Ki-67 and TUNEL staining (P < .001). Radiofrequency hyperthermia mediate chemotherapy-induced VX2 cell killing regulated cell death mechanisms include enhance penetration of doxorubicin and HSP70 interacting at several points on apoptotic and immune signaling pathways, leads to inhibition of apoptosis of cell death at the HCC tumor ablation margin.

Supplementary Tables 1 and 2 and Supplementary Figures 1 Through 7 from Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas

PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation

Survival Outcomes and Safety of Programmed Cell Death/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials

Synergistic effect of a novel cantharidin analog LB1 with doxorubicin in chemotherapy against hepatocellular carcinoma cells

Supplementary Materials and Methods from Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas

Inhibition of Protein Phosphatase 2A Sensitizes Pancreatic Cancer to Chemotherapy by Increasing Drug Perfusion Via HIF-1α-VEGF Mediated Angiogenesis.

CBL0137 Administration Suppresses Human Hepatocellular Carcinoma Cells Proliferation and Induces Apoptosis Associated with Multiple Cell Death Related Proteins.

Abstract No. 506 Image-guided Radiofrequency Hyperthermia-Enhanced Direct Chemotherapy of Hepatic Tumors: the Underlying Biomolecular Mechanisms

LB-100 Sensitizes Hepatocellular Carcinoma Cells to the Effects of Sorafenib During Hypoxia by Activation of Smad3 Phosphorylation

Supplemental Materials and Methods and Supplemental Figure Legends from Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells

Supplementary Figure 6-10 from Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells

Effect of 1B50-1, a novel antibody, combined with chemotherapeutic drugs on proliferation of hepatocellular carcinoma cells

Supplementary Tables 1-2 from Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation

Nano co-delivery of doxorubicin and plumbagin achieves synergistic chemotherapy of hepatocellular carcinoma

Supplementary Figure 5 from Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair

Supplementary Figure 3 from Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions

Suppl. Tables and Suppl. Figure Legends from Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy

Data from Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells

[Study on PI3K Inhibitor LY294002 for Chemotherapeutic Sensitization in Diffuse Large B Cell Lymphoma Cell Lines].

Hepatocyte Growth Factor/c-Met Signaling Pathway Decreases Doxorubicin Sensitivity in Hepatocellular Carcinoma in Vitro

Supplementary Figure 1 from Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions